Free Biopharma Daily Stock Updates - 04/26/21

$XBI $139 +4%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$GILD +1% Announces plans to expand Remdesivir in India. source


$MRNA +2% Entered into agreement with Sanofi to fill/finish servies for 200 million doses of COVID vaccine in September 2021. source


$IMNM -7% SARS-CoV-2 antibody cocktail neutralizes UK, South Africa, Brazil, and California variants in preclinical testing. source



Pipeline Updates

$SRRK +5% Issuance of US patent related to inhibitors of myostatin activation. source


$RETA +15% FDA acceptance of NDA for bardoxolone for CKD by Alport syndrome, PDUFA date 2/25/22. source


$KRYS +3% Modifications to the statistical analysis plan for the ph 3 study of B-Vec for DEB based on FDA feedback. source


$ALDX +8% Schedules conference call 4/27/21 to announce ph 3 INVIGORATE results. source


$ZSAN +8% PK study of Qtrypta to initiate in June 2021; required for the NDA resubmission. source


$VYGR +16% FDA clears IND for VY-HTT01 gene therapy candidate for Huntington's Disease. source


$PIRS +6% Entering into exclusive product license with Boston Pharmaceuticals for PRS-342. source


$QURE +8% FDA clinical hold removed on hemophilia B program. source


$IMAB +1% Olamkicept Phase 2 trial reports positive topline results. source


$NLTX +6% Clinical hold on NL-201 removed, Phase 1 trial will begin recruiting over next several months. source


$KPTI +4% EMA validated MAA to expand label in the EU for NEXPOVIO in combo with bortezomib and dexamethasone to treat MM. source


$AXSM +11% AXS-05 NDA accepted by FDA, PDUFA date set for August 22, 2021. source


$AZN +1% Selumetinib recommended for approval in the EU for neurofibromatosis type 1 and plexiform neurofibromas. source


$AZN +1% Tagrisso recommended for approval in the EU for lung cancer. source


$AZN +1% Nirsevimab Phase 3 MELODY trial met primary endpoint in RSV infections. source



Finance Updates

$ESPR +4% Receives final revenue-based funding of $50M from Oberland Capital. source


$ESPR +4% Expands partnership with Daiichi Sankyo, $30M up front and up to $175M in milestone payments. source

0 comments